17 Jun Designing Radiopharmaceutical Studies for IND-Enabling Success: What Regulators Expect
Preclinical Studies with Radiopharmaceuticals: IND-Enabling Guidance and Study Design
Introduction
Preclinical evaluation is an integral part of the development of investigational new drugs (IND), including radiopharmaceuticals. Radiopharmaceuticals are radio-labelled formulations used for diagnostic, therapeutic, and disease monitoring purposes within the context of both nuclear medicine and pharmaceutical research. While diagnostic radiopharmaceuticals are used to image organ function, trace biological processes, and quantify metabolism or IND target engagement, therapeutic radiopharmaceuticals are typically used in the field of oncology, whereby ionising radiation of a conjugated radionuclide induces targeted cell death. Because radiopharmaceuticals require the use of radioactive compounds, regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require stringent controls around their development, manufacturing, handling, transport, and use. This article will consider guidance specifically surrounding the development of preclinical radiopharmaceutical research studies, considering imaging requirements, dosimetry, and toxicology, and highlighting how sponsors can enable IND success through partnership with a preclinical imaging provider experienced in nuclear medicine.
Radiopharmaceutical Research
Radiopharmaceuticals involve local delivery of radionuclides to targeted lesions for the diagnosis and treatment of multiple diseases. Radiopharmaceutical therapy has attracted growing interest for the treatment of refractory diseases, specifically those which do not respond well to currently available treatments, owing to its ability to selectively induce irreversible cell damage whilst sparing surrounding healthy tissue. Radiopharmaceutical techniques have been nurtured over the last 80 years, from the first application of 131I for diagnosing and treating thyroid disorders, to the development of more than 60 approved radiopharmaceuticals now used across oncology, cardiology, neurology, and other disease areas. With several new radiopharmaceutical approvals and label expansions made in the last few years alone, particularly in the field of oncology, it is no surprise that regulatory agencies are tightening their oversight of the development, manufacturing, and clinical indications associated with radiopharmaceutical IND submissions.
IND-Enabling Studies for Radiopharmaceuticals
The International Atomic Energy Agency (IAEA) has published stringent guidance for preclinical studies with radiopharmaceuticals. The guidance emphasizes the need for radiopharmaceutical development to come under more rigorous processes than conventional pharmaceuticals due to the combination of chemical and radiological risks involved. The guidance considers that the development of a new radiopharmaceutical is a multidisciplinary process, involving contributions from different fields of research including nuclear chemistry, synthetic chemistry, pharmaceutics, molecular biology, and drug pharmacology. Due to the inherent complexity of this field, developers must consider the research design as a regimented sequence of interconnected protocols requiring a highly specialized infrastructure, individual expertise, and coordinated teamwork.
Key recommendations include:
- Comprehensive characterization of radiopharmaceutical behavior prior to first-in-human use, including biodistribution, pharmacokinetics, dosimetry, toxicity, and radiometabolite analysis.
- Adherence to good laboratory practice (GLP) and robust quality assurance procedures to generate reliable nonclinical data suitable for regulatory review.
- Standardized protocols for in vitro, in vivo, and ex vivo testing to support clinical translation.
- Stringent facilities, equipment, and personnel training for handling radioactive materials safely.
- Extensive quality control and documentation throughout development, manufacturing, preparation, and administration processes.
The guidance places considerable emphasis on the integration of appropriate imaging, dosimetry, toxicology, and data reporting procedures throughout preclinical development, to effectively characterize biodistribution, estimate radiation exposure, and evaluate safety prior to clinical translation.
Perceptive Discovery
Sponsors have to ensure both due diligence and strategic imperative when considering preclinical RLT study design and development. Many pharmaceutical companies are joining forces with experienced clinical trial imaging providers, particularly those with the experience and infrastructure needed to facilitate global radiopharmaceutical drug development.
In a field where precision is everything, the cost of inexperience is high. Missteps in isotope selection, imaging protocols, or dosimetry strategy can derail IND submission timelines, compromise data integrity, and put patient safety at risk. That’s why 80% of sponsors trust Perceptive, bringing the scientific rigor, operational depth, and regulatory foresight needed to facilitate radiopharmaceutical IND success.
With decades of experience in meeting regulatory expectations and generating decision-grade data, Perceptive is considered the industry’s most experienced partner in radioligand and radiopharmaceutical therapy, supporting over 100 clinical trials and thousands of preclinical programs across a wide range of targets and tumor types.
Learn more about Perceptive Imaging Services today.
Resources
- Signal Transduct Target Ther. Radiopharmaceuticals and their applications in medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC11697352/
- IAEA. Guidance for preclinical studies with radiopharmaceuticals. https://www-pub.iaea.org/MTCD/publications/PDF/PUB2031_web.pdf
Disclaimer: The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Opinions expressed are those of the Contributing Writer and do not represent the views of MedicalResearch.com or Eminent Domains Inc. Some links are sponsored. Products, services and providers are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc. Always seek the advice of your physician or other qualified health provider and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on June 18, 2026 by Marie Benz MD FAAD